Analysis of the relationship between parameters of controlled ovarian stimulation and de novo chromosomal abnormalities in chromosomal structural abnormalities
10.3760/cma.j.cn101441-20240618-00221
- VernacularTitle:控制性卵巢刺激相关参数与染色体结构异常中新发染色体异常的关系分析
- Author:
Jing ZHANG
1
;
Ye TIAN
1
;
Fang LI
1
;
Yan ZHANG
1
;
Xueru SONG
1
;
Wenyan TIAN
1
;
Haixia CHEN
1
;
Xiaohong BAI
1
Author Information
1. 天津医科大学总医院妇产科生殖中心 天津市女性生殖健康与优生重点实验室，天津 300052
- Publication Type:Journal Article
- Keywords:
Controlled ovarian stimulation;
Preimplantation genetic testing for structural rearrangements;
De novo chromosomal abnormalities
- From:
Chinese Journal of Reproduction and Contraception
2024;44(11):1164-1169
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the parameters of controlled ovarian stimulation (COS) on the occurrence of de novo chromosomal abnormalities in preimplantation genetic testing for structural rearrangements (PGT-SR) cycles. Methods:A retrospective analysis control study was performed on 70 PGT-SR cycles and 39 preimplantation genetic testing for monogenic (PGT-M) embryos in the Department of Obstetrics and Gynecology, Reproductive Medicine Center of Tianjin Medical University General Hospital from January 2023 to August 2024. The correlation between de novo chromosomal abnormalities and ovarian stimulation protocol, duration and total dosage of gonadotropin (Gn) used, estradiol and progesterone levels on human chorionic gonadotropin (hCG) trigger day in COS were analyzed. Results:1) Biopsies were performed on 341 blastocysts in the PGT-SR group and 196 blastocysts in the PGT-M group. There was a significant difference in aneuploid rate of blastocyst between PGT-SR and PGT-M groups [62.1% (205/330) vs. 30.2% (58/192), P<0.001]. There was no significant difference in the incidence of de novo chromosomal abnormalities, between PGT-SR and PGT-M groups ( P>0.05). 2) After adjusting for couples' age and blastocyst grade, there were no significant differences in the incidence of de novo chromosomal abnormalities among different ovarian stimulation protocols, different duration and total dosage of Gn used, different estradiol and progesterone levels on hCG trigger day (all P>0.05). 3) There were no significant differences the incidence of de novo whole, fragment and complex chromosomal abnormalities among different ovarian stimulation protocols, different duration and total dosage of Gn used, different estradiol and progesterone levels on hCG trigger day (all P>0.05). Conclusion:Different ovarian stimulation protocols, duration and total dosage of Gn used, estrogen and progesterone levels on hCG trigger day don't affect the whole de novo chromosomal abnormalities, de novo whole, fragment, complex chromosomal abnormalities in patients with structural chromosomal abnormalities.
